Modafinil in Multiple Sclerosis

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00142402
• Date of registration: 01/09/2005
• Prospective Registration: No
• Primary sponsor: Kessler Foundation
• Public title: Modafinil in Multiple Sclerosis
• Scientific title: Modafinil for Improving New Learning and Memory in Multiple Sclerosis
• Date of first enrolment: June 2003
• Target sample size: 20
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00142402
• Study type: Interventional
• Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
• Phase: N/A

Countries of recruitment

United States

Contacts

• Name: Nancy D Chiaravalloti, PhD
• Affiliation: KMRREC

Key inclusion & exclusion criteria

Inclusion Criteria:

- Must understand English, diagnosis of Multiple Sclerosis

Exclusion Criteria:

- Significant language comprehension deficits, age greater than 60, less than 1-month
post most recent exacerbation, current treatment with corticosteroids, significant
neurological history aside from MS (e.g. epilepsy, TBI), significant substance abuse
history as documented by the MAST,27 significant psychiatric history (e.g.
Schizophrenia, Bipolar Disorder, Major Depression), non-fluency in the English
language.



Age minimum: 18 Years
Age maximum: 60 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Multiple Sclerosis

Intervention(s)

Drug: Modafinil

Primary Outcome(s)

Scores on memory tests at 3 weeks and 6 weeks

Secondary Outcome(s)

Scores on emotional measures at 3 weeks and 6 weeks

Scores on fatigue measures at 3 weeks and 6 weeks

Secondary ID(s)

ndcnmss2004

PP0911

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Multiple Sclerosis Society